PTC Therapeutics Receives Complete Response Letter for Ataluren ' s NDA

SOUTH PLAINFIELD, N.J., Oct. 25, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Office of Drug Evaluation I of the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news